Case Report

Xinju Chen, Xiaoqi Chen, Chuanlei Zhang, Xinting Wang, Changwei Yuan, He Yang, Lixia Yang*

One case of iodine-125 therapy – A new minimally invasive treatment of intrahepatic cholangiocarcinoma

https://doi.org/10.1515/biol-2022-0473
received September 18, 2021; accepted July 07, 2022

Abstract: Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer associated with a poor prognosis. ICC accounts for about 10% of primary liver malignancies but with increasing incidence in recent years. Recently, some studies suggested that minimally interventional therapy can be used in the treatment of ICC. However, there are few references on interventional therapy for the clinical treatment of ICC.

Herein we reported a case of a 48-year-old man who suffered from ICC. The patient was diagnosed with ICC by computerized tomography scan and pathological biopsy. The patient was completely cured by minimally interventional therapy with iodine-125 seed implantation. These results provide an important reference for the treatment option of ICC.

Keywords: intrahepatic cholangiocarcinoma, transcatheter arterial chemoembolization, iodine-125

1 Background

Intrahepatic cholangiocarcinoma (ICC) is a primary malignant tumor originating from secondary bile ducts and above the peripheral small bile ducts in the liver [1]. Due to its intrahepatic localization, early symptoms are not obvious, and most patients are diagnosed with advanced ICC [2]. Although in the past few years, there have been several reports pointing to the general value of liver resection in the management of ICC. However, there is still great uncertainty regarding the surgical management of large and advanced ICC [3]. Recently, many studies have shown that interventional therapy is a potential treatment method for ICC [4,5]. Iodine-125 brachytherapy is a technique that has been used recently to treat spine and bone metastases, as well as inoperable brain tumors and head and neck cancers [6–9]. As an interventional treatment, brachytherapy via iodine-125 seed implantation has developed over the past decades and has become an acceptable palliative treatment for patients with unresectable cholangiocarcinoma [10]. It has been reported that self-expandable metallic stent combined with catheter-loaded iodine-125 seeds brachytherapy significantly improves outcomes and could be a safe and effective treatment for advanced extrahepatic cholangiocarcinoma [11]. However, little research related to the iodine-125 brachytherapy for ICC have been reported till now. Herein we reported a case of 48-year-old...
man who suffered from ICC and completely cured by min-
imally interventional therapy with iodine-125 seed implan-
tation. These results provide the important reference for
treatment option of ICC.

1.1 Case presentation

A 48-year-old man with no relevant medical history was
admitted to our hospital for acute abdominal pain and
fatigue on September 12, 2016. Palpation of the right
quadrant of the patient showed tenderness, but the test
of Murphy sign was negative. On the second day after
admission, the patient underwent computerized tomo-
graphy (CT) scan, showing a 5.5 cm × 5.1 cm lesion adja-
cent to the liver capsule (Figure 1). Combined with the
results of pathological biopsy, the patient was diagnosed
with ICC.

Based on the history, symptoms, signs, and auxiliary
examination, the patient was diagnosed with ICC II (AJCC-UICC
TNM stage: 8) and cachexia (ECOG score: 2). Meanwhile, after
multidisciplinary consultation, the surgical treatment was not
recommended due to the poor nutritional status. Hence, the
interventional treatment was recommended after improving
the nutritional status of the patient. Finally, transcatheter
arterial chemoembolization (TACE) was performed on the
patient on September 18, 2016. Briefly, the catheter was super-
selectively intubated into the tumor supplying artery through
the skin. And the end of the tumor supplying artery was
embolized with iodized oil emulsion (10 mL) containing
chemotherapy drugs (epirubicin hydrochloride needle 10 mg).
The patient had no apparent discomfort after surgery.

The patient’s liver function was re-examined after 3 days
of treatment, with TB: 11 µmol/L, ALT: 20 U/L, AST:
19 U/L, and ALB: 30 g/L.

CT scan of the liver was performed 1 month after
TACE treatment. The results showed abnormal right lobe
with margin atrophy. The patchy mixed density shadow
was observed in the right posterior lobe of liver, and
speckled shadow of iodide deposition were observed at
the edge (Figure 2). Furthermore, it was assessed as dis-
ease stability (SD) by modified Response Evaluation Cri-
teria in Solid Tumor (mRECIST) criteria.

These results suggested that ICC is not sensitive to
TACE treatment. After a multidisciplinary consultation
and discussion, the patient underwent minimally inter-
ventional therapy with iodine-125 seed implantation.
Briefly, based on preoperative CT scan, treatment
planning system (TPS; Beijing Hang Kelin Technology Development Co., LTD) was used to simulate approximate dose distribution of solid tumor at prescribed dose and to determine the particle number and spatial distribution (V100 ≥ 95% and D90 ≥ 100%). In order to prevent the particles from entering the blood vessels and migrating, the total radiation dose was 120 Gy, the particle spacing was about 1 cm, and the particles were implanted 1 cm away from the large blood vessels. 3D printing templates were made by TPS before treatment. The radioactive particles were placed percutaneously through a 3D-printed template under CT guidance. Complications were observed after operation, including whether there was bleeding under the liver capsule, large blood vessels and whether there was particle displacement or gas embolism in the heart. Moreover, a CT scan was performed after the surgery to make sure the surgery went well. The instruments used in the present operation included pistol type particle implantation device (Figure 3), 18G particle implantation needle, and iodine-125 radioactive particles with an activity of 2.22E + 7 Bq (Beijing Atomic Technology Co., LTD).

In order to avoid bleeding, only two injections were used. We adjusted the needle in the liver for multi-point ablation, always avoiding penetrating the liver capsule. The frame heads were adjusted to fan shape, and iodine-125 seeds were planted so that they were distributed in a fan shape with a distance of 1 cm between each two seeds (Figure 4).

After 3 months of treatment, CT scan showed that the lesion was atrophic (Figure 5). The mRECIST assessment showed complete remission (CR). The patient’s liver function was re-examined on January 1, 2021, and the important clinical indicators of liver function results were as follows: TB: 11.2 μmol/L, ALT: 2018 U/L, AST: 16.9 U/L, and ALB: 47 g/L. Moreover, re-examinations after discharge showed that the lesions were completely necrotic and no signs of recurrence until last CT scan on January 1, 2021 (Figure 6), and mRECIST assessment was CR.

**Informed consent:** Informed consent has been obtained from all individuals included in this study.

**Ethical approval:** The research related to human use has been complied with all the relevant national regulations,
institutional policies and in accordance with the tenets of the Helsinki Declaration, and has been approved by the ethics committee of The First Affiliated Hospital of Henan University of Chinese Medicine.

2 Discussion

Surgical resection is currently the main modality for the treatment of ICC. Due to the insidious onset of ICC, no obvious clinical manifestations, and obvious invasiveness, only 35% of patients are fully eligible for surgery. However, due to the high malignancy of ICC, the post-operative recurrence and metastasis rate is high [12].

The efficacy of TACE in the treatment of ICC is uncertain. Other minimally invasive interventions include radiofrequency ablation and iodine-125 particle implantation. In this case, we found that ICC was not sensitive to TACE treatment, and radiofrequency ablation treatment was too damaging to the patient. After consultation, we treated the patient with iodine-125 seed implantation and the patient completely was cured by minimal interventional therapy with iodine-125 seed implantation.

The main clinical treatment of ICC is surgical resection; however, some types of ICC are not suitable for surgery, or the risks of surgery are too high for the patients. Interventional therapy has become the main treatment for these patients. At present, minimally interventional therapy includes TACE and local treatment (ablation, seed implantation, and external radiotherapy) [13]. However, in the present study, we found that this case with ICC was not sensitive to TACE treatment.

As one of the curative methods for liver cancer, radiofrequency ablation has the advantages of wide application, simple operation, and quick recovery after surgery. However, for tumors in some special parts (such as near the biliary tract, gallbladder, large blood vessels, large tumors protruding from the liver capsule, etc.), it is difficult to cure large tumors (greater than 5 cm) with radiofrequency ablation. Actually, radiofrequency ablation is suitable for tumors smaller than 3 cm. In this study, the lesions of this patient were non-encapsulated and had obvious edge enhancement, indicating that the lesions were infiltrative growth and the surrounding tumor cells were actively growing. If radiofrequency ablation is performed, the ablation range needs to be expanded, at least 1–2 cm beyond the periphery to ensure complete inactivation of the tumor, which will cause greater damage.

During the last few decades, several brachytherapy methods for ICC have been reported. For example, 90Y radioembolization therapy, a form of brachytherapy, has been regarded as a locoregional treatment in unresectable ICC patients [14–16]. Iodine-125 seed implantation is a method of internal radiotherapy to treat tumors [17]. It targets tumor cell by continuously releasing low-dose gamma rays at close distances but does less damage to other tissues around the tumor [18,19]. Accumulating evidence reveals that iodine-125 seed implantation could be a safe and effective treatment for advanced extrahepatic cholangiocarcinoma [11]. In this case, we used minimally interventional therapy with iodine-125 seed implantation. Iodine-125 particles can slowly release gamma rays, which can directly destroy tumor tissue. The radiation range of each particle is 17 mm, and the half-life is 59.43 days. According to the inverse square law of tissue dose distance, the radiation dose outside the planned area is gradually attenuated, so that the target lesion and the surrounding 1–2 cm tissue can be killed to the maximum extent, which has the effect of similar enlarged ablation, and avoids the “thermal deposition” of adjacent blood vessels during.

Figure 6: CT-scan showing that lesions were completely necrotic and no signs of recurrence after 5 years of treatment.
radiofrequency ablation “effect.” Moreover, it does little damage to the surrounding tissue, and is especially suitable for tumors in special parts.

In this case, the tumor was large and had invaded the liver capsule and intrahepatic blood vessels. The physical fitness score showed that the patient was not suitable for surgery, and radiofrequency ablation was difficult to achieve a one-time radical cure. Therefore, iodine-125 seed implantation was selected. However, it is very difficult to make the iodine-125 seed evenly distributed around the lesion. We introduced in detail the operation details and matters needing attention. During the execution of the iodine-125 seed implantation operation, we adjusted the frame head to make it fan-shaped, and implanted iodine-125 seed around the lesion. After iodine-125 implantation treatment, the patient has survived tumor-free for more than 4 years, which proves that iodine-125 particles have obvious effects in the treatment of ICC. Our team has accumulated some experience in the application of iodine-125 in the treatment of hepatocellular carcinoma. We have analyzed 77 cases (including 33 cases of seed implantation and 44 cases of radiofrequency ablation) with solitary tumors less than 5 cm in the liver. The local recurrence rates of the two groups of patients at 1, 2, and 3 years were compared. The results showed that there was no significant difference in the recurrence rate between the seed implantation group and the radiofrequency ablation group in terms of controlling the local recurrence of small hepatocellular carcinoma [20]. However, iodine-125 particles have been less reported in the treatment of larger ICC. This interventional approach needs to be validated in more future experiments. This case provides an important reference for the selection of ICC treatment options.

3 Conclusion

Collectively, our case provides successful experience and new inspiration for the treatment of ICC. Therefore, interventional therapy with iodine-125 seed implantation may be a promising therapeutic strategy for ICC.

Funding information: This work was supported by National Science and Technology Major Project of the Ministry of Science and Technology of China (2018ZX10303502).

Conflict of interest: Authors state no conflict of interest.

Data availability statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

[1] Sirica AE, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Adv Cancer Res. 2021;149:321–87.

[2] Mandrekar P, Cardinale V. Periostin and mesothelin: Potential predictors of malignant progression in intrahepatic cholangiocarcinoma. Hepatol Commun. 2018;2(5):481–3.

[3] Spratt B, Kozan E, Sinnott M. Analysis of uncertainty in the surgical department: Durations, requests and cancellations. Aust Health Rev. 2019;43(6):706–11.

[4] Seidensticker R, Seidensticker M, Doegen K, Mohnike K, Schütte K, Stübs P, et al. Extensive use of interventional therapies improves survival in unresectable or recurrent intrahepatic cholangiocarcinoma. Gastroenterol Res Pract. 2016;2016:8732521.

[5] Ierardi AM, Angileri SA, Patella F, Panella S, Lucchina N, Petre EN, et al. The role of interventional radiology in the treatment of intrahepatic cholangiocarcinoma. Med Oncol. 2017;34(1):11.

[6] Jiao D, Wu G, Ren J, Han X. Radiofrequency ablation versus 125I seed brachytherapy for painful metastases involving the bone. Oncotarget. 2016;7(52):87523–31.

[7] Liu Y, He C, Li Y, Chen YX, Yang L, Li TY, et al. Clinical efficacy of computed tomography-guided iodine-125 seed implantation therapy for patients with metastatic epidural spinal cord compression: A retrospective study. J Cancer Res Ther. 2019;15(4):807–12.

[8] Chin J, Rumble RB, Kollmeier M, Heath E, Efstathiou J, Dorff T, et al. Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology/Cancer Care Ontario joint guideline update. J Clin Oncol. 2017;35(15):1737–43.

[9] Mohler J, Antonarakis E. NCCN guidelines updates: Management of prostate cancer. J Natl Compr Canc Netw. 2019;17(5.5):583–6.

[10] Li H, Chen L, Zhu G, Yao X, Dong R, Guo J. Interventional treatment for cholangiocarcinoma. Front Oncol. 2021;11:671327.

[11] Wang Y, Man Z, Hu X, Zhou L, Jin H, Liu H, et al. Percutaneous biliary stent with intraluminal brachytherapy versus palliative surgery in the management of extrahepatic cholangiocarcinoma. Int J Clin Oncol. 2021;26(5):933–40.

[12] El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am. 2019;28(4):587–99.

[13] Schicho A, Pereira PL, Pützler M, Michalik K, Albrecht T, Nolte-Ennsting C, et al. Degradable starch microspheres transcatheter arterial chemoembolization (DSM-TACE) in intrahepatic cholangiocellular carcinoma (ICC): Results from a national multi-center study on safety and efficacy. Med Sci Monit. 2017;23:796–800.

[14] Mosconi C, Cappelli A, Ascanio S, Pettinari I, Modestoins F, Renzulli M, et al. Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocarcinoma. Future Oncol (London, Engl). 2017;13(15):1301–10.

[15] Jiao F, Long L, Ding S, Xie X, Jia L, Lu F. Complete genome sequencing and clinical analysis of intrahepatic hepatitis B virus cccDNA from HCC. Microb Pathog. 2017;109:49–55.

[16] Reimer P, Virarkar M, Binnenheil M, Justinger M, Schön M, Tatsch K. Prognostic factors in overall survival of patients with unresectable intrahepatic cholangiocarcinoma treated by means of yttrium-90 radioembolization: Results in therapy-naïve patients. Cardiovasc Intervent Radiol. 2018;41(5):744–52.
[17] Kou F, Gao S, Liu S, Wang X, Chen H, Zhu X, et al. Preliminary clinical efficacy of iodine-125 seed implantation for the treatment of advanced malignant lung tumors. J Cancer Res Ther. 2019;15(7):1567–73.

[18] Chen X, Zhu F, Wang B, Zhou Y, Xiong H, Fan T, et al. Clinical effect of iodine-125 seed implantation in patients with primary liver cancer and its effect on Th1/Th2 cells in peripheral blood. J Oncol. 2021;2021:6199732.

[19] Zhang L, Lu J, Wang Z, Cheng Y, Teng G, Chen K. Clinical efficacy of computed tomography-guided iodine-125 seed implantation therapy in patients with advanced spinal metastatic tumors. Onco Targets Ther. 2016;9:7–12.

[20] Dan X, Xiaoqi C, Chuanlei Z, Xinting W, Yuhui K, Xinju C. Clinical evaluation of CT-guided 125I-seed implantation in the treatment of small hepatocellular carcinoma. J Clin Radiol. 2021;40(9):1785–9.